Swiss biotechnology company Lonza Group AG (Lonxa) (SWX: LONN) has agreed with British pharmaceutical company AstraZeneca Plc (STO: AZN) (LON: AZN) to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, Reuters news agency reported on Friday.
According to Lonxa, AZD7442 is in Phase I clinical studies and AstraZeneca plans to advance the combination into Phase III trials in the coming weeks.
Lonza will manufacture drug substance for AZD7442 at its facilities in the US.
These operations are expected to commence in the first half of 2021.
Transneural Therapeutics presents new data on TN-001 at 64th Annual Meeting of ACNP
US FDA accepts IND application for AskBio's AB-1009
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
ElpasBio partners with Fosun Kairos on AlloJoin stem cell therapy
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
WuXi Biologics granted UK GMP certification for two manufacturing facilities in Wuxi
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes